≡ FDA Approves New SPRYCELÃ (Dasatinib) Product Labeling For Patients With Chronic-Phase CML Part 5
About SPRYCEL On June 28, 2006, the U.S. Food and Drug Administration (FDA) granted hurry up confirmation of SPRYCEL (pronounced ’spris-el), an oral inhibitor of multiple tyrosine kinases, all for the employment of adults within all three point of CML (chronic-, accelerated-, or myeloid or lymphoid blast-phase) near rubbing or intolerance to prior […]
